Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Acquired by GAMMA Investing LLC

GAMMA Investing LLC grew its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 9,296.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,175 shares of the biopharmaceutical company's stock after acquiring an additional 8,088 shares during the period. GAMMA Investing LLC's holdings in Agios Pharmaceuticals were worth $240,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in AGIO. Vanguard Group Inc. lifted its position in Agios Pharmaceuticals by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company's stock valued at $185,045,000 after purchasing an additional 85,339 shares during the period. Jefferies Financial Group Inc. acquired a new position in shares of Agios Pharmaceuticals in the 4th quarter valued at about $49,290,000. Frazier Life Sciences Management L.P. lifted its holdings in shares of Agios Pharmaceuticals by 2.5% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 1,069,754 shares of the biopharmaceutical company's stock valued at $35,152,000 after buying an additional 25,600 shares during the period. Fisher Asset Management LLC boosted its stake in shares of Agios Pharmaceuticals by 12.3% in the fourth quarter. Fisher Asset Management LLC now owns 960,661 shares of the biopharmaceutical company's stock worth $31,567,000 after buying an additional 105,333 shares during the last quarter. Finally, Deutsche Bank AG boosted its stake in shares of Agios Pharmaceuticals by 39.7% in the fourth quarter. Deutsche Bank AG now owns 935,252 shares of the biopharmaceutical company's stock worth $30,732,000 after buying an additional 265,637 shares during the last quarter.

Agios Pharmaceuticals Stock Performance

Shares of Agios Pharmaceuticals stock traded down $0.71 on Wednesday, hitting $32.71. The company's stock had a trading volume of 316,501 shares, compared to its average volume of 654,061. The company has a market capitalization of $1.89 billion, a price-to-earnings ratio of 2.91 and a beta of 0.73. The firm has a fifty day moving average price of $30.92 and a 200-day moving average price of $32.38. Agios Pharmaceuticals, Inc. has a 1 year low of $23.42 and a 1 year high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share for the quarter, topping the consensus estimate of ($1.80) by $0.25. Agios Pharmaceuticals had a negative return on equity of 2.75% and a net margin of 1,798.26%. The business had revenue of $8.73 million during the quarter, compared to the consensus estimate of $9.86 million. As a group, analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Insiders Place Their Bets

In related news, Director Jacqualyn A. Fouse sold 7,497 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, April 10th. The stock was sold at an average price of $25.90, for a total value of $194,172.30. Following the sale, the director now directly owns 149,220 shares in the company, valued at approximately $3,864,798. The trade was a 4.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 4.93% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on AGIO. Wall Street Zen downgraded Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Monday, May 19th. Scotiabank cut their target price on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating for the company in a report on Friday, May 2nd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $58.60.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.